Peter Lebowitz: Three Phase 3 lung cancer readouts in the Presidential Symposium and 4 late-breaker presentations in genitourinary cancers

Peter Lebowitz, SVP, Global Oncology Therapeutic Area Head at Janssen/Johnson and Johnson, made the following post on LinkedIn:

“Three Phase 3 lung cancer readouts in the Presidential Symposium and 4 late-breaker presentations in genitourinary cancers (bladder cancer and prostate cancer).

It’s great to be on the ground at ESMO – European Society for Medical Oncology in Madrid with our best-in-industry Johnson & Johnson Innovative Medicine Oncology team seeing first-hand the advances in solid tumor science and innovation for patients.”

Source: Peter Lebowitz/LinkedIn